Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
ImmunityBio, Inc. (IBRX) had Return on Equity of 12.40% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$38.28M |
|
$-61.94M |
|
$0.38M |
|
$37.90M |
|
$102.97M |
|
$-64.68M |
|
$2.59M |
|
$-62.09M |
|
$-62.09M |
|
$-61.96M |
|
$-61.96M |
|
$-61.96M |
|
$-61.96M |
|
$-64.68M |
|
$-60.82M |
|
919.86M |
|
919.86M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$314.88M |
|
$114.26M |
|
$187.02M |
|
$501.90M |
|
$61.75M |
|
$477.09M |
|
$939.72M |
|
$1.00B |
|
$-499.57M |
|
$-513.53M |
|
$-499.57M |
|
1.01B |
|
| Cash Flow Statement Financials | |
$-304.94M |
|
$-149.80M |
|
$400.24M |
|
$143.91M |
|
$89.43M |
|
$-54.48M |
|
$36.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.10 |
|
-- |
|
-- |
|
-21.22 |
|
-0.95 |
|
99.00% |
|
-168.95% |
|
-168.95% |
|
-- |
|
-162.19% |
|
-161.80% |
|
$-308.78M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
0.42 |
|
0.90 |
|
100.08 |
|
|
Return on Equity |
12.40% |
12.07% |
|
-12.34% |
|
275.60% |
|
$-0.49 |
|
$-0.34 |
|
$-0.33 |
|